Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Takeda Pharmaceutical Co stock price, quote, forecast and news

4502.T
JP3463000004
853849

Price

4,263.00 JPY
Today +/-
-0.05 JPY
Today %
-0.19 %
P

Takeda Pharmaceutical Co stock price

JPY
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Takeda Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Takeda Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Takeda Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Takeda Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Takeda Pharmaceutical Co Stock Price History

DateTakeda Pharmaceutical Co Price
9/9/20244,263.00 JPY
9/6/20244,271.00 JPY
9/5/20244,295.00 JPY
9/4/20244,333.00 JPY
9/3/20244,398.00 JPY
9/2/20244,349.00 JPY
8/30/20244,333.00 JPY
8/29/20244,352.00 JPY
8/28/20244,339.00 JPY
8/27/20244,340.00 JPY
8/26/20244,303.00 JPY
8/23/20244,391.00 JPY
8/22/20244,379.00 JPY
8/21/20244,369.00 JPY
8/20/20244,364.00 JPY
8/19/20244,304.00 JPY
8/16/20244,324.00 JPY
8/15/20244,292.00 JPY
8/14/20244,236.00 JPY
8/13/20244,125.00 JPY

Takeda Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Takeda Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Takeda Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Takeda Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Takeda Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Takeda Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Takeda Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Takeda Pharmaceutical Co’s growth potential.

Takeda Pharmaceutical Co Revenue, EBIT and net profit per share

DateTakeda Pharmaceutical Co RevenueTakeda Pharmaceutical Co EBITTakeda Pharmaceutical Co Net Income
2027e4.59 T JPY503.99 B JPY281.38 B JPY
2026e4.52 T JPY401.98 B JPY204.74 B JPY
2025e4.46 T JPY228.26 B JPY104.22 B JPY
20244.26 T JPY430.79 B JPY144.07 B JPY
20234.03 T JPY550.9 B JPY317.02 B JPY
20223.57 T JPY545.49 B JPY230.06 B JPY
20213.2 T JPY335.72 B JPY376.01 B JPY
20203.29 T JPY286.5 B JPY44.24 B JPY
20192.1 T JPY183.49 B JPY135.19 B JPY
20181.77 T JPY202.84 B JPY186.89 B JPY
20171.73 T JPY191.25 B JPY114.94 B JPY
20161.81 T JPY147.16 B JPY80.17 B JPY
20151.78 T JPY88.69 B JPY-145.78 B JPY
20141.69 T JPY151.73 B JPY106.66 B JPY
20131.56 T JPY122.51 B JPY131.24 B JPY
20121.51 T JPY265.03 B JPY124.16 B JPY
20111.42 T JPY367.08 B JPY247.87 B JPY
20101.47 T JPY420.21 B JPY297.74 B JPY
20091.54 T JPY306.47 B JPY234.39 B JPY
20081.37 T JPY423.12 B JPY355.45 B JPY
20071.31 T JPY458.5 B JPY335.81 B JPY
20061.21 T JPY402.81 B JPY312.9 B JPY
20051.12 T JPY381.03 B JPY277.09 B JPY

Takeda Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (T JPY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (T JPY)EBIT (B JPY)EBIT MARGIN (%)NET INCOME (B JPY)NET INCOME GROWTH (%)DIV. (JPY)DIV. GROWTH (%)SHARES (B)DOCUMENTS
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.730.770.80.840.840.840.920.961.011.051.091.121.211.311.371.541.471.421.511.561.691.781.811.731.772.13.293.23.574.034.264.464.524.59
-6.023.854.680.360.349.294.374.324.083.863.367.957.675.3311.90-4.71-3.186.313.208.635.091.66-4.172.2218.4556.93-2.8411.6112.855.874.541.351.57
45.4044.5245.9146.4547.3448.4153.1760.1466.3871.2975.2075.1476.7378.5779.7381.1880.5577.6371.2971.2671.0270.7070.3867.7471.9968.9266.8968.9168.9969.1166.54---
0.330.340.370.390.40.410.490.580.670.750.820.840.931.031.11.251.181.11.081.111.21.261.271.171.271.452.22.22.462.782.84000
75.9182.4397.11110.35113.74142.22171.44226.1281.24310.69371.63381.03402.81458.5423.12306.47420.21367.08265.03122.51151.7388.69147.16191.25202.84183.49286.5335.72545.49550.9430.79228.26401.98503.99
10.4310.6812.1213.1513.5116.8418.5723.4727.9829.7034.2133.9333.2335.1330.7819.9228.6625.8617.567.878.974.998.1411.0411.468.758.7110.5015.2813.6810.105.128.9010.98
47.6351.4359.8471.3881.6191.76119.63146.86235.66271.41284.93277.09312.9335.81355.45234.39297.74247.87124.16131.24106.66-145.7880.17114.94186.89135.1944.24376.01230.06317.02144.07104.22204.74281.38
-7.9916.3619.2814.3312.4330.3722.7660.4715.174.98-2.7512.927.325.85-34.0627.03-16.75-49.915.70-18.73-236.68-154.9943.3862.59-27.66-67.28749.90-38.8137.80-54.56-27.6696.4637.43
----------------------------------
----------------------------------
0.880.880.890.890.890.890.880.880.880.880.890.890.890.870.850.810.790.790.790.790.790.790.790.790.790.971.571.571.581.571.56000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Takeda Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Takeda Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (T JPY)RECEIVABLES (B JPY)OTHER REC. (B JPY)INVENTORIES (T JPY)OTHER CURRENT LIAB. (B JPY)CURRENT ASSETS (T JPY)TANGIBLE ASSETS (T JPY)LONG-T. INVEST. (B JPY)LONG-T. REC. (B JPY)INTANGIBLE ASSETS (T JPY)GOODWILL (T JPY)OTHER NON-CURRENT ASSETS (B JPY)NON-CURRENT ASSETS (T JPY)TOTAL ASSETS (T JPY)LIABILITIESCOMMON STOCK (T JPY)ADDITIONAL PAID-IN CAPITAL (T JPY)RETAINED EARNINGS (T JPY)OTHER EQUITY (T JPY)UNREAL. GAINS/LOSSES (B JPY)EQUITY (T JPY)LIABILITIES (B JPY)PROVISIONS (B JPY)OTHER SHORT-TERM LIAB. (T JPY)SHORT-TERM DEBTS (B JPY)LONG-TERM DEBT PORTION (B JPY)SHORT-TERM REC. (T JPY)LONG-T. LIAB. (T JPY)DEFERRED TAXES (B JPY)OTHER LIAB. (B JPY)LONG-T. LIABILITIES (T JPY)DEBT (T JPY)TOTAL CAPITAL (T JPY)
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                             
0.340.350.390.440.490.540.640.720.941.171.321.521.861.81.680.760.880.870.460.550.850.710.560.380.380.730.6510.880.550.47
230.1242.69258.77248.61230.28225.73233.54254.19234.09201.94209.15225.14236.37261.44247.29301.45279.7293.1341.82342.37375.94400.85376.49356.45360.83657.68670.71707.49617.52575.43612.44
0000000000000000000066.7265.9854.0888.3367.9691.44114.21105.23106.86106.2685.17
0.10.10.10.10.110.110.110.10.10.090.090.090.10.110.120.130.140.140.20.230.250.260.250.230.210.920.760.750.850.991.21
27.8529.1136.1740.8948.5239.6348.460.9173.784.39105.31128.09180.82191.03195.38283.7272.26281.8286.53335.4844.5177.47129.18213.4561.89598.43271.48143.48141.1176.1178.21
0.690.720.790.830.880.911.031.141.351.541.731.972.372.362.241.481.571.591.281.461.591.521.371.261.082.992.472.712.592.42.56
0.210.240.230.230.230.220.240.220.210.20.230.220.220.240.240.260.320.410.490.510.540.530.550.530.541.331.391.451.581.691.99
115.68113.32122.68138.06155.28154.79152.71374.36394.06297.71360.42314.95400.57413.23297.18200.26204.44191.58226.04216.01234.89281.97186.19303.05304.39299.92369.46348.35330.13378.86430.61
13.4211.983.662.962.522.211.963.162.841.981.551.610.190.250.230.340.370.360.991.0400000000000
000000000.0100000.010.010.460.380.30.360.431.140.940.741.061.014.754.173.913.824.274.27
0000000000.01000000.280.260.221.151.260.810.820.781.021.034.244.014.034.414.795.41
18.4320.7325.4522.923.3428.3443.015.014.413.174.1430.7448.5752.0861.7577.7786.7483.3166.0682.63249.2206.7189.75173.38142.96176.46411.95454.11445.15429.33445.08
0.360.390.380.390.420.410.440.610.620.520.610.580.670.710.611.281.251.22.32.52.982.782.453.093.0310.810.3510.210.5811.5612.55
1.051.111.171.221.31.331.471.751.972.062.342.553.043.072.852.762.822.793.583.964.574.33.824.354.1113.7912.8212.9113.1813.9615.11
                                                             
0.050.050.050.050.050.060.060.060.060.060.060.060.060.060.060.060.060.060.060.060.060.060.060.070.081.641.671.671.681.681.68
0.040.040.040.040.040.050.050.050.050.050.050.050.050.050.050.050.050.050.050.040.040.060.070.070.091.651.681.691.711.731.75
0.530.570.620.670.740.790.90.991.181.391.621.832.062.32.522.012.172.272.252.241.91.61.521.511.561.61.371.511.481.541.39
0000000-0.010.02-0.01-0.07-0.0700.02-0.16-0.19-0.25-0.37-0.44-0.260.410.350.270.220.270.30.070.320.911.52.49
0000000122.39115.7272.79127.66125.34171.84185.65130.3479.6391.1973.9687.0577.9660.7760.77067.9873.0446.3822.8941.9822.0712.4715.73
0.610.650.70.760.830.911.011.211.421.571.7822.352.612.62.012.122.092.012.162.472.141.931.942.075.244.815.235.86.457.32
105.33113.56115.59117.4111.38113.98115.4697.368977.673.1970.7578.277.4472.4768.1372.8283.07101.95118.69129.35124.37135.21125.71133.71212.35211.63232.11295.93307.45319.96
50.3556.1465.9571.6576.322.4527.2532.02103.4399.06114.33132.27159.9147.01167.24130.55156.45157.52205.45218.4300000000000
0.110.090.10.090.10.130.160.210.170.160.180.150.240.210.190.270.190.190.20.270.520.790.490.70.61.361.381.521.651.831.63
9.7511.5413.1113.9711.1410.9915.698.675.94.676.848.35.454.963.363.213.291.33241.411.81.2300405.050.025005.010.070.290.260.25
000022.35000000000001.250.0100154.18154.18228.46139.970484.94581.822.08203.71339.34367
0.270.280.30.290.320.280.310.350.370.340.370.370.490.440.430.470.430.440.750.610.81.070.861.370.742.552.181.772.152.482.31
0.030.030.030.03000000000000.020.020.020.320.560.70.630.540.60.994.774.514.614.144.044.48
000000062.7359.6136.0177.0875.49106.22124.6959.95141.7141.73112.3301.76322.13280.6156.13123.47153.490.73783.36765.08576.54473.15295.18118.16
116.38129.51120.26116.65116.01111.75104.7889.3474.4970.3364.5558.1952.2244.2938.097672.7984.47133.82240.46240.58287.64292.44278.23275.18504.37646.14772.18734.2783.22927.03
0.150.160.150.150.120.110.10.150.130.110.140.130.160.170.10.230.230.210.751.121.231.070.961.031.356.055.925.965.355.125.52
0.420.430.450.440.440.390.420.50.510.450.510.50.650.610.530.710.660.651.511.732.032.141.812.42.098.618.097.747.497.67.83
1.031.091.151.21.271.31.431.711.932.022.32.533.233.132.722.782.743.523.894.54.283.744.344.1613.8512.912.9713.2914.0615.16
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Takeda Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Takeda Pharmaceutical Co's financial health and stability.

Assets

Takeda Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Takeda Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Takeda Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Takeda Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B JPY)DEPRECIATION (B JPY)DEFERRED TAXES (M JPY)CHANGES IN WORKING CAPITAL (B JPY)NON-CASH ITEM (B JPY)PAID INTEREST (B JPY)PAID TAXES (B JPY)NET CASH FLOW FROM OPERATING ACTIVITIES (T JPY)CAPITAL EXPENDITURES (M JPY)CASH FLOW FROM INVESTING ACTIVITIES (B JPY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B JPY)INTEREST INCOME AND EXPENSES (M JPY)NET DEBT CHANGE (T JPY)NET CHANGE IN EQUITY (M JPY)CASH FLOW FROM FINANCING ACTIVITIES (T JPY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (JPY)TOTAL DIVIDENDS PAID (M JPY)NET CHANGE IN CASH FLOW (B JPY)FREE CASH FLOW (M JPY)SHARE-BASED COMPENSATION (M JPY)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
202.76263.08373.43431.9446.14441.1517.96625.38576.84398.55415.83371.57252.48129.71109.56-143.0383.48115.51186.71109.0144.29376.17230.17317.04
33.3633.6128.4329.9628.0831.2328.7328.8231.69118.08114.83106.72150.19201.11215.74260.95197.38171.43182.13272.45583.65559.67583.15664.4
000000000000000000000000
-70.42-108.75-116.34-162.06-151.65-189.32-97.58-340.69-203.6-261.83-146.06-150.34-45.81-9.66-180.25-208.2711.9-41.0973.67-92.22-130.4962.7857.68-331.91
-3.2523.63-44.93-36.35-11.4636.25-75.54-104.23-112.4471.48-3.43-1.02-20.29-13.443.28272.87-267.27-6.29-43.3139.06172.9312.31252.11327.63
1.170.920.870.430.370.340.370.250.141.771.421.331.853.244.945.234.896.978.3734.91127.21107.35108.21108.56
72.6392.04132.85157.66163.4194.76161.84356.98263.8220.37138.66141.82152.0822.7167.3874.133.6440.7529.8844.91226.77201.69140.42185.97
0.160.210.240.260.310.320.370.210.290.330.380.330.340.310.150.180.030.240.40.330.671.011.120.98
-35,423-26,941-37,523-33,477-54,160-53,669-32,093-29,151-32,618-39,464-86,960-124,165-61,904-95,763-78,519-108,718-84,857-112,027-128,262-134,114-217,710-236,468-186,037-633,689
-51.68-58.25125.24140.15-139.32-72.316.57116.39101.75-767.26-117.52-99.26-1,093.96-111.38-158.6191.35-71.21-655.69-93.34-2,835.7292.12393.53-198.13-607.1
-16.25-31.31162.76173.63-85.16-18.6438.66145.54134.37-727.79-30.5624.91-1,032.06-15.61-80.09200.0713.65-543.6634.92-2,701.58509.83630-12.0926.59
000000000000000000000000
0-0-0-000-0-0-0-0-0-00.54-00.25-0.120.050.48-0.153.16-0.59-0.66-0.6-0.29
0000000-213,734-128,758-280,268-34-50-16-240-17,587-22,346-23,117-18,756-1,172-3,737-2,141-77,531-26,929
-0.03-0.04-0.05-0.06-0.06-0.07-0.09-0.32-0.26-0.43-0.15-0.150.39-0.150.1-0.3-0.120.29-0.332.95-1.01-1.09-1.07-0.71
-703.00-363.00-2,123.00-2,507.00-999.00-1,653.00-1,509.00-1,564.00-1,970.00-2,956.00-3,321.00-3,775.00-3,479.00-3,554.00-5,323.00-22,273.00-10,938.00-20,733.00-15,099.00-71,143.00-132,804.00-142,352.00-108,592.00-117,732.00
-28,009-36,610-48,541-54,435-60,869-74,958-85,529-98,757-129,167-142,446-143,554-142,055-142,013-142,118-142,133-141,637-141,538-141,688-141,893-142,952-282,582-283,357-283,665-279,416
77.96119.76336.64324.6453.13188.24361.9121.46-34.45-855.1694.420.23-418.4691.33120.47-10.81-203.82-131.97-24.93407.57-64.48328.61-116.53-316.17
127,036184,614203,063229,973256,962265,590341,481180,129259,877286,812294,206202,774274,667211,94769,81673,799-59,366127,539270,938194,187452,671774,463937,068343,467
000000000000000000000000

Takeda Pharmaceutical Co stock margins

The Takeda Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Takeda Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Takeda Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Takeda Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Takeda Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Takeda Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Takeda Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Takeda Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Takeda Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Takeda Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Takeda Pharmaceutical Co Margin History

Takeda Pharmaceutical Co Gross marginTakeda Pharmaceutical Co Profit marginTakeda Pharmaceutical Co EBIT marginTakeda Pharmaceutical Co Profit margin
2027e66.54 %10.98 %6.13 %
2026e66.54 %8.9 %4.53 %
2025e66.54 %5.12 %2.34 %
202466.54 %10.1 %3.38 %
202369.11 %13.68 %7.87 %
202268.99 %15.28 %6.45 %
202168.91 %10.5 %11.76 %
202066.89 %8.71 %1.34 %
201968.92 %8.75 %6.45 %
201871.99 %11.46 %10.56 %
201767.74 %11.04 %6.64 %
201670.38 %8.14 %4.44 %
201570.7 %4.99 %-8.2 %
201471.02 %8.97 %6.3 %
201371.26 %7.87 %8.43 %
201271.29 %17.56 %8.23 %
201177.63 %25.86 %17.46 %
201080.55 %28.66 %20.31 %
200981.18 %19.92 %15.24 %
200879.73 %30.78 %25.85 %
200778.57 %35.13 %25.73 %
200676.73 %33.23 %25.81 %
200575.14 %33.93 %24.67 %

Takeda Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Takeda Pharmaceutical Co earnings per share therefore indicates how much revenue Takeda Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Takeda Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Takeda Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Takeda Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Takeda Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Takeda Pharmaceutical Co Revenue, EBIT and net profit per share

DateTakeda Pharmaceutical Co Sales per ShareTakeda Pharmaceutical Co EBIT per shareTakeda Pharmaceutical Co Earnings per Share
2027e2,908.5 JPY0 JPY178.36 JPY
2026e2,863.51 JPY0 JPY129.78 JPY
2025e2,825.45 JPY0 JPY66.06 JPY
20242,725.41 JPY275.36 JPY92.09 JPY
20232,565.48 JPY350.92 JPY201.94 JPY
20222,262.92 JPY345.87 JPY145.87 JPY
20212,032.24 JPY213.36 JPY238.96 JPY
20202,101.38 JPY182.93 JPY28.25 JPY
20192,169.03 JPY189.77 JPY139.82 JPY
20182,250.61 JPY257.84 JPY237.56 JPY
20172,203.94 JPY243.36 JPY146.25 JPY
20162,293.14 JPY186.72 JPY101.71 JPY
20152,260.74 JPY112.78 JPY-185.37 JPY
20142,141.37 JPY192.07 JPY135.01 JPY
20131,971.22 JPY155.07 JPY166.13 JPY
20121,910.04 JPY335.48 JPY157.17 JPY
20111,796.69 JPY464.66 JPY313.76 JPY
20101,858 JPY532.59 JPY377.37 JPY
20091,901.53 JPY378.82 JPY289.72 JPY
20081,621.23 JPY498.97 JPY419.17 JPY
20071,500.19 JPY527.01 JPY385.98 JPY
20061,369.73 JPY455.15 JPY353.56 JPY
20051,268.88 JPY430.55 JPY313.09 JPY

Takeda Pharmaceutical Co business model

Takeda Pharmaceutical Co Ltd is a Japanese company that operates in the pharmaceutical industry. The company was founded in 1781 by Chobei Takeda as a traditional pharmacy specializing in herbal medicine. Nowadays, the company is a leading player in the global pharmaceutical industry. Business model: Takeda aims to help people worldwide through the development of groundbreaking therapies and drugs. The company has a strong research and development department that focuses on the discovery of new therapies and the improvement of existing medications. Takeda has made global partnerships and acquisitions to leverage the combination of science and technology and ensure better patient care. Divisions: Takeda operates in four main divisions: Gastrointestinal (GI), Oncology, Rare Diseases, and Neuroscience. In the GI division, the company is a global leader in the treatment of gastrointestinal diseases such as Crohn's disease and ulcerative colitis. The Oncology division aims to develop novel cancer therapies and provide patients with a higher quality of life. The Rare Diseases division specializes in the development of medications for rare diseases. The Neuroscience division focuses on developing medications to combat nervous system disorders such as Alzheimer's and Parkinson's. Products: Takeda's product range includes a variety of medications used worldwide to treat various diseases. One example is enzyme replacement therapy, which is administered to patients with a rare disease. Another example is Entyvio, a medication used to treat Crohn's disease and ulcerative colitis. Takeda also has medications in the Oncology division, such as Adcetris, a therapeutic agent against certain lymphomas and leukemia. In summary, Takeda Pharmaceutical Co Ltd is a leading company in the global pharmaceutical industry. The company's business model is based on the development of groundbreaking therapies and medications to improve patient care. With a focus on the GI, Oncology, Rare Diseases, and Neuroscience divisions, Takeda offers a variety of products for the treatment of various diseases. Takeda Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Takeda Pharmaceutical Co SWOT Analysis

Strengths

Takeda Pharmaceutical Co Ltd possesses various strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong global presence with operations in multiple countries, which allows it to access diverse markets and benefit from global demand. Additionally, Takeda has a broad range of pharmaceutical products, including both prescription drugs and over-the-counter medications, enabling it to cater to a wide customer base. The company also boasts a robust research and development (R&D) pipeline, investing heavily in innovative solutions to address various diseases and medical conditions.

Another notable strength of Takeda is its extensive partnerships and collaborations with other pharmaceutical companies and research institutions. This provides the company with access to cutting-edge technologies, as well as shared knowledge and resources. Furthermore, Takeda has a strong brand reputation built upon its commitment to delivering high-quality, reliable, and safe pharmaceutical products to consumers worldwide.

Weaknesses

Despite its strengths, Takeda Pharmaceutical Co Ltd also faces certain weaknesses that it must address. One such weakness is the company's heavy reliance on a few key products for a significant portion of its revenue. This concentration poses a risk as any negative impact on those products could have a significant financial effect on Takeda. Moreover, Takeda operates in a highly competitive industry where pricing pressures and regulatory challenges may limit its growth opportunities.

Another weakness lies in Takeda's historical focus on the Japanese market, which has limited its international market share compared to some of its global competitors. This dependency on the domestic market may hinder the company's ability to expand rapidly and diversify its revenue streams.

Opportunities

Takeda Pharmaceutical Co Ltd can explore several opportunities to strengthen its position in the market and drive growth. Firstly, the increasing focus on personalized medicine and advancements in precision therapies present an opportunity for Takeda to leverage its R&D capabilities and develop targeted treatment options. Additionally, the growing aging population in many countries creates a demand for drugs related to age-related diseases and conditions, which Takeda can tap into.

Furthermore, Takeda can capitalize on emerging markets, particularly in Asia and Latin America, where healthcare spending and access to pharmaceutical products are on the rise. By expanding its presence in these regions, the company can unlock new revenue streams and gain a competitive advantage over its peers. Moreover, digital healthcare advancements offer opportunities for Takeda to enhance its product offerings and develop innovative solutions for remote patient monitoring, telemedicine, and data analytics.

Threats

Takeda Pharmaceutical Co Ltd faces various threats that may impact its business operations. One significant threat is the increasing regulatory scrutiny and requirements imposed on the pharmaceutical industry, which can lead to delays in product approvals and increased compliance costs. Additionally, Takeda operates in a constantly evolving patent landscape, where the expiration of patents for key drugs exposes the company to potential revenue loss from generic drug competition.

Another threat is the risk of disruptions in the global supply chain, such as natural disasters or political uncertainties, which can disrupt Takeda's manufacturing processes and distribution networks. Furthermore, intense competition from both established pharmaceutical companies and emerging players poses a threat to Takeda's market share and profitability.

Takeda Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Takeda Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Takeda Pharmaceutical Co shares outstanding

The number of shares was Takeda Pharmaceutical Co in 2023 — This indicates how many shares 1.57 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Takeda Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Takeda Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Takeda Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Takeda Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Takeda Pharmaceutical Co Stock splits

In Takeda Pharmaceutical Co's history, there have been no stock splits.

Takeda Pharmaceutical Co dividend history and estimates

In 2023, Takeda Pharmaceutical Co paid a dividend amounting to 184 JPY. Dividend means that Takeda Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Takeda Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Takeda Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Takeda Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Takeda Pharmaceutical Co Dividend History

DateTakeda Pharmaceutical Co Dividend
2027e185.41 JPY
2026e183.58 JPY
2025e185.23 JPY
2024192 JPY
2023184 JPY
2022180 JPY
2021180 JPY
2020180 JPY
2019180 JPY
2018180 JPY
2017180 JPY
2016180 JPY
2015180 JPY
2014180 JPY
2013180 JPY
2012180 JPY
2011180 JPY
2010180 JPY
2009182 JPY
2008172 JPY
2007152 JPY
2006166 JPY
2005141 JPY

Takeda Pharmaceutical Co dividend payout ratio

In 2023, Takeda Pharmaceutical Co had a payout ratio of 278.65%. The payout ratio indicates the percentage of the company's profits that Takeda Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Takeda Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Takeda Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Takeda Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Takeda Pharmaceutical Co Payout Ratio History

DateTakeda Pharmaceutical Co Payout ratio
2027e184.82 %
2026e208.28 %
2025e187.06 %
2024159.13 %
2023278.65 %
2022123.4 %
202175.33 %
2020637.23 %
2019128.74 %
201875.77 %
2017123.07 %
2016176.97 %
2015-97.1 %
2014133.32 %
2013108.35 %
2012114.53 %
201157.37 %
201047.7 %
200962.82 %
200841.03 %
200739.38 %
200646.95 %
200545.03 %
Unfortunately, there are currently no price targets and forecasts available for Takeda Pharmaceutical Co.

Takeda Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202444.2 JPY60.71 JPY (37.34 %)2025 Q1
3/31/20240.78 JPY-2.01 JPY (-357.79 %)2024 Q4
12/31/202328.78 JPY67.59 JPY (134.84 %)2024 Q3
9/30/202336.8 JPY-31 JPY (-184.23 %)2024 Q2
6/30/202369.87 JPY57.51 JPY (-17.69 %)2024 Q1
3/31/202313.57 JPY20.03 JPY (47.57 %)2023 Q4
12/31/202275.28 JPY76.7 JPY (1.89 %)2023 Q3
9/30/202238.63 JPY39.75 JPY (2.91 %)2023 Q2
6/30/202271.84 JPY67.94 JPY (-5.43 %)2023 Q1
3/31/20226.02 JPY-6.95 JPY (-215.36 %)2022 Q4
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Takeda Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

93/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

82

Environment

Scope 1 - Direct Emissions
316,000
Scope 2 - Indirect emissions from purchased energy
283,000
Scope 3 - Indirect emissions within the value chain
4,716,000
Total CO₂ emissions
599,000
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
❌
Pesticides
❌
Palm Oil
❌
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies✅
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Takeda Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
4.27395 % Nomura Asset Management Co., Ltd.67,425,939464,6003/31/2024
3.22617 % Sumitomo Mitsui Trust Asset Management Co., Ltd.50,896,134-10,134,70010/13/2023
2.84752 % The Vanguard Group, Inc.44,922,58668,2003/31/2024
2.35720 % Capital Research Global Investors37,187,284-19,688,3683/31/2024
2.28326 % BlackRock Japan Co., Ltd.36,020,80036,020,8004/15/2024
2.20024 % Nikko Asset Management Co., Ltd.34,711,1002,204,10010/13/2023
2.09815 % BlackRock Fund Advisors33,100,48833,097,0884/15/2024
2.04424 % JPMorgan Securities Japan Co., Ltd.32,250,0006,628,0009/30/2023
1.91839 % Daiwa Asset Management Co., Ltd.30,264,603-57,0133/31/2024
1.61777 % Norges Bank Investment Management (NBIM)25,521,9661,408,91912/31/2023
1
2
3
4
5
...
10

Takeda Pharmaceutical Co Executives and Management Board

Mr. Christophe Weber56
Takeda Pharmaceutical Co President, Chief Executive Officer, Representative Director (since 2014)
Compensation 1.73 B JPY
Mr. Costa Saroukos52
Takeda Pharmaceutical Co Chief Financial Officer, Director (since 2019)
Compensation 676 M JPY
Mr. Masami Iijima72
Takeda Pharmaceutical Co Chairman of Board of Directors, Independent Director
Compensation 43 M JPY
Mr. Koji Hatsukawa71
Takeda Pharmaceutical Co Independent Director
Compensation 43 M JPY
Ms. Emiko Higashi64
Takeda Pharmaceutical Co Independent Director
Compensation 43 M JPY
1
2
3
4

Takeda Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Aukett Swanke Group Stock
Aukett Swanke Group
SupplierCustomer--0,16-0,85-0,73-0,56-0,42
Legochem Biosciences Stock
Legochem Biosciences
SupplierCustomer0,970,33-0,78-0,74-0,130,18
Mitsubishi Stock
Mitsubishi
SupplierCustomer0,960,550,450,89-0,05-0,45
Zydus Lifesciences Stock
Zydus Lifesciences
SupplierCustomer0,950,11-0,35-0,890,24-0,05
Mizuho Medy Stock
Mizuho Medy
SupplierCustomer0,91-0,020,69-0,560,15-0,09
Sosei Group Stock
Sosei Group
SupplierCustomer0,900,44-0,49-0,89-0,41-0,16
BlackLine Stock
BlackLine
SupplierCustomer0,880,18-0,44-0,91-0,13-0,04
Nolato B Stock
Nolato B
SupplierCustomer0,88-0,06-0,78-0,91-0,50-0,53
KDDI Stock
KDDI
SupplierCustomer0,850,010,810,900,33-0,18
Kadmon Holdings, Inc. Stock
Kadmon Holdings, Inc.
SupplierCustomer0,84-0,050,810,880,46-
1
2
3
4
5
...
14

Most common questions regarding Takeda Pharmaceutical Co

What values and corporate philosophy does Takeda Pharmaceutical Co represent?

Takeda Pharmaceutical Co Ltd represents a focus on values and corporate philosophy that prioritize patient-centricity, integrity, and dedication to improving people's lives. Takeda is committed to delivering innovative and high-quality medicines, aiming to contribute to the health of patients worldwide. With a legacy spanning over 239 years, Takeda upholds a core mission to strive towards better health and a sustainable future. Their dedication to ethical practices, collaborative partnerships, and continuous innovation reinforces Takeda Pharmaceutical Co Ltd's position as a leading global pharmaceutical company.

In which countries and regions is Takeda Pharmaceutical Co primarily present?

Takeda Pharmaceutical Co Ltd is primarily present in various countries and regions worldwide. As a leading global pharmaceutical company, Takeda operates in multiple key markets, including Japan, the United States, Europe, and emerging markets in Asia, Latin America, and Africa. With a strong international presence, Takeda continues to expand its reach to bring innovative medicines and healthcare solutions to patients across the globe.

What significant milestones has the company Takeda Pharmaceutical Co achieved?

Takeda Pharmaceutical Co Ltd has achieved numerous significant milestones throughout its history. One key accomplishment was its establishment in 1781, making it one of the oldest pharmaceutical companies in Japan. Takeda has continued to innovate and excel in the healthcare industry, expanding its global presence and becoming the largest pharmaceutical company in Asia. It has made groundbreaking advancements in various therapeutic areas, such as gastroenterology, oncology, and neuroscience. Takeda's acquisition of Shire in 2019 further solidified its position as a leading global biopharmaceutical company. These achievements highlight Takeda Pharmaceutical Co Ltd's commitment to improving lives through its innovative medicines and therapies.

What is the history and background of the company Takeda Pharmaceutical Co?

Takeda Pharmaceutical Co Ltd is a renowned pharmaceutical company with a rich history and strong global presence. Founded in 1781 in Osaka, Japan, Takeda has grown to become one of the largest pharmaceutical companies in the world. Over the years, Takeda has focused on research and development, manufacturing, and marketing of a wide range of pharmaceutical products. With a commitment to improving the health of people worldwide, they have expanded their operations to over 80 countries. Takeda's success can be attributed to its dedication to innovation, high-quality products, and a focus on patient-centered healthcare solutions. Today, Takeda remains at the forefront of the industry, striving to address unmet medical needs and improve patients' lives globally.

Who are the main competitors of Takeda Pharmaceutical Co in the market?

The main competitors of Takeda Pharmaceutical Co Ltd in the market include multinational pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies are prominent players in the global pharmaceutical industry, with a diverse range of healthcare products and a significant market presence. Takeda Pharmaceutical Co Ltd faces competition from these established competitors in various therapeutic areas, including oncology, gastroenterology, and rare diseases. The company strives to maintain its competitive edge by leveraging its research and development capabilities, innovative product portfolio, and strategic collaborations, allowing it to compete effectively in the dynamic pharmaceutical market.

In which industries is Takeda Pharmaceutical Co primarily active?

Takeda Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Takeda Pharmaceutical Co?

Takeda Pharmaceutical Co Ltd. operates under a research-based pharmaceutical business model. As a leading global biopharmaceutical company, Takeda focuses on discovering, developing, and distributing innovative medicines and healthcare solutions. The company is committed to improving the health and well-being of people worldwide through its strong portfolio of prescription drugs and therapies. Takeda's business model emphasizes leveraging its expertise in areas such as oncology, gastroenterology, neuroscience, and rare diseases to deliver life-changing treatments and therapies. With a dedication to innovation and collaboration, Takeda remains at the forefront of advancing healthcare and improving patient outcomes.

What is the P/E ratio of Takeda Pharmaceutical Co 2024?

The Takeda Pharmaceutical Co P/E ratio is 46.29.

What is the P/S ratio of Takeda Pharmaceutical Co 2024?

The Takeda Pharmaceutical Co P/S ratio is 1.56.

What is the AlleAktien quality score of Takeda Pharmaceutical Co?

The AlleAktien quality score for Takeda Pharmaceutical Co is 5/10.

What is the revenue of Takeda Pharmaceutical Co 2024?

The Takeda Pharmaceutical Co revenue is 4.26 T JPY.

How high is the profit of Takeda Pharmaceutical Co 2024?

The Takeda Pharmaceutical Co profit is 144.07 B JPY.

What is the business model of Takeda Pharmaceutical Co

Takeda Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1781. It is headquartered in Osaka and currently employs over 49,000 people worldwide. The company operates in over 70 countries and offers a wide range of innovative medicines. Takeda focuses on the fields of internal medicine, oncology, gastroenterology, and neurology.

What is the Takeda Pharmaceutical Co dividend?

Takeda Pharmaceutical Co pays a dividend of 180 JPY distributed over 2 payouts per year.

How often does Takeda Pharmaceutical Co pay dividends?

Takeda Pharmaceutical Co pays out a dividend 2 times a year.

What is the Takeda Pharmaceutical Co ISIN?

The ISIN of Takeda Pharmaceutical Co is JP3463000004.

What is the Takeda Pharmaceutical Co WKN?

The WKN of Takeda Pharmaceutical Co is 853849.

What is the Takeda Pharmaceutical Co ticker?

The ticker of Takeda Pharmaceutical Co is 4502.T.

How much dividend does Takeda Pharmaceutical Co pay?

Over the past 12 months, Takeda Pharmaceutical Co paid a dividend of 192 JPY . This corresponds to a dividend yield of about 4.5 %. For the coming 12 months, Takeda Pharmaceutical Co is expected to pay a dividend of 185.23 JPY.

What is the dividend yield of Takeda Pharmaceutical Co?

The current dividend yield of Takeda Pharmaceutical Co is 4.5 %.

When does Takeda Pharmaceutical Co pay dividends?

Takeda Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Takeda Pharmaceutical Co?

Takeda Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Takeda Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 185.23 JPY are expected. This corresponds to a dividend yield of 4.35 %.

In which sector is Takeda Pharmaceutical Co located?

Takeda Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Takeda Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Takeda Pharmaceutical Co from 12/1/2024 amounting to 98 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Takeda Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Takeda Pharmaceutical Co in the year 2023?

In the year 2023, Takeda Pharmaceutical Co distributed 184 JPY as dividends.

In which currency does Takeda Pharmaceutical Co pay out the dividend?

The dividends of Takeda Pharmaceutical Co are distributed in JPY.

All fundamentals about Takeda Pharmaceutical Co

Our stock analysis for Takeda Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Takeda Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.